Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 1/19/2022 | $3.00 → $2.75 | Buy | HC Wainwright & Co. |
| 7/27/2021 | $3.00 | Buy | Ladenburg Thalmann |
S-8 - electroCore, Inc. (0001560258) (Filer)
10-K - electroCore, Inc. (0001560258) (Filer)
8-K - electroCore, Inc. (0001560258) (Filer)
4 - electroCore, Inc. (0001560258) (Issuer)
4 - electroCore, Inc. (0001560258) (Issuer)
4 - electroCore, Inc. (0001560258) (Issuer)
ROCKAWAY, N.J., April 01, 2026 (GLOBE NEWSWIRE) -- electroCore, Inc. (NASDAQ:ECOR), a commercial-stage bioelectronic medicine and wellness company, announced today the publication of new clinical findings in Frontiers in Neuroscience titled "Adjunctive non-invasive vagus nerve stimulation for chronic mild traumatic brain injury with comorbid post-traumatic stress disorder: a post-hoc analysis" by Drs. Michael Ament, Peter Staats, Norianne Theresa Ingram, and Emily Leonard, demonstrating the potential benefits of adjunctive non-invasive vagus nerve stimulation (nVNS) in patients with chronic mild traumatic brain injury (mTBI) and comorbid post-traumatic stress disorder (PTSD). The publicat
ROCKAWAY, N.J., March 31, 2026 (GLOBE NEWSWIRE) -- electroCore, Inc. (the "Company"), (NASDAQ:ECOR), a commercial-stage bioelectronic medicine and wellness company, today announced that Seth Abrams will join electroCore, effective April 1, 2026, as the Company's VP, Sales, and Michael Fox will join electroCore, effective April 13, 2026, as the Company's Chief Operating Officer. The Compensation Committee of electroCore's Board of Directors granted 30,000 restricted stock units ("RSUs") to Mr. Abrams and 70,000 RSUs to Mr. Fox in connection with the commencement of their employment. The RSUs were granted as an inducement material to their commencement of employment pursuant to NASDAQ Listin
ROCKAWAY, N.J., March 30, 2026 (GLOBE NEWSWIRE) -- electroCore, Inc. (NASDAQ:ECOR), a commercial-stage bioelectronic medicine and wellness company, today announced the issuance of two new U.S. patents that further bolster the Company's already extensive intellectual property portfolio. These additions underscore electroCore's position as a leader in non-invasive vagus nerve stimulation (nVNS) technology and demonstrate how a nimble small-cap innovator can build one of the most robust patent portfolios in the field. The newly issued patents are: • U.S. Patent No. 12,208,263, entitled "Devices and Methods for Vagal Nerve Stimulation" was issued on January 28, 2026 and covers innovative meth
HC Wainwright & Co. reiterated coverage of electroCore with a rating of Buy and set a new price target of $2.75 from $3.00 previously
Ladenburg Thalmann initiated coverage of electroCore with a rating of Buy and set a new price target of $3.00
Maxim Group resumed coverage of electroCore with a rating of Buy and set a new price target of $3.00
4 - electroCore, Inc. (0001560258) (Issuer)
4 - electroCore, Inc. (0001560258) (Issuer)
4 - electroCore, Inc. (0001560258) (Issuer)
ROCKAWAY, N.J., Sept. 03, 2025 (GLOBE NEWSWIRE) -- electroCore, Inc. (NASDAQ:ECOR), a commercial-stage bioelectronic medicine and wellness company, today announced that Elena Bonfiglioli, an accomplished healthcare executive, has been appointed to electroCore's Board of Directors, effective September 2, 2025. Ms. Bonfiglioli's appointment follows the retirement from the Board of Peter Cuneo. Ms. Bonfiglioli has been working in the health sector for more than two decades. She currently serves as Microsoft's Global Business Leader for Healthcare, Pharma Life Sciences, and the International clinical applications' solutions, responsible for go-to-market, commercial, and partnerships, enabling
ROCKAWAY, N.J., Aug. 05, 2025 (GLOBE NEWSWIRE) -- electroCore, Inc. (NASDAQ:ECOR), a commercial-stage bioelectronic medicine and wellness company, announced today that James C. Theofilos has been appointed to the Board of Directors, effective August 1, 2025. "I'm honored to have been appointed to the Board of Directors at electroCore," said Mr. Theofilos. "For nearly two decades, the Theofilos family has deeply believed in the power of the vagus nerve and proudly supported electroCore as both an early investor and founding partner. At Microsoft, I've had the privilege of serving as the global finance lead for our healthcare and life sciences business — working alongside some of the worl
ROCKAWAY, N.J., June 11, 2024 (GLOBE NEWSWIRE) -- electroCore, Inc. (NASDAQ:ECOR), a commercial-stage bioelectronic medicine and wellness company, announced today that its stock is on the preliminary additions list for inclusion in the Russell Microcap® Index after its 2024 annual reconstitution. The newly reconstituted indexes will take effect after the market close on June 28, 2024, with the newly effective reconstituted family of indices beginning trading after the open of trading on July 1, 2024, according to a preliminary list of additions posted by FTSE Russell on May 24, 2024. "We are pleased to have been selected to join the Russell Microcap® Index," said Brian Posner, Chief Finan
Record full year 2025 net sales of $32.0, an increase of 27% over $25.2 million for the full year 2024 driven by 25% annual growth in our U.S. prescription business and 97% increase in general wellness sales Announces the retirement of Dan Goldberger as Chief Executive Officer in addition to other key executive management changes Company to host a conference call and webcast today, March 19, 2026, at 4:30pm EDT ROCKAWAY, N.J., March 19, 2026 (GLOBE NEWSWIRE) -- electroCore, Inc. (NASDAQ:ECOR) ("electroCore" or the "Company"), a bioelectronic technology company, today announced full year 2025 financial results. Reported record full year of 2025 revenue of $32.0 million, an increase of a
Net sales of $8.7 million increased 33% vs. Q3 2024; YTD net sales of $22.8 million increased 26% vs. first nine months of 2024 Cash, cash equivalents, restricted cash, and marketable securities ("Total Cash") of $13.2 million as of September 30, 2025 Company to host a conference call and webcast today, November 5, 2025, at 4:30 p.m. EDT ROCKAWAY, N.J., Nov. 05, 2025 (GLOBE NEWSWIRE) -- electroCore, Inc. (NASDAQ:ECOR) ("electroCore" or the "Company"), a bioelectronic technology company, today announced financial results for the three and nine months ended September 30, 2025. Recent Highlights Record revenue for Q3 2025 of $8.7 million, a 33% increase over Q3'2024Year-to-date revenue
Net sales of $7.4 million increased 20% vs. Q2'2024; YTD net sales of $14.1 million increased 22% vs. first half of 2024 Cash, cash equivalents, restricted cash, and marketable securities of $7.4 million as of June 30, 2025 Company to host a conference call and webcast today, August 6, 2025, at 4:30 p.m. EDT ROCKAWAY, N.J., Aug. 06, 2025 (GLOBE NEWSWIRE) -- electroCore, Inc. (NASDAQ:ECOR) ("electroCore" or the "Company"), a commercial-stage bioelectronic technology company, today announced financial results for the three and six months ended June 30, 2025. Recent Highlights Record revenue for Q2'2025 of $7.4 million, a 20% increase over Q2'2024Year-to-Date revenue of $14.1 million, a
SC 13D/A - electroCore, Inc. (0001560258) (Subject)
SC 13G/A - electroCore, Inc. (0001560258) (Subject)
SC 13D - electroCore, Inc. (0001560258) (Subject)
**Analysis of Recent Insider Purchase at electroCore Inc.** An insider purchase was recently made at electroCore Inc. by Goldberger Daniel S on June 6, 2024. This transaction involved the purchase of $247,587 worth of shares, equating to 38,505 units at an average price of $6.43 per share. As a result of this purchase, Goldberger's direct ownership in the company increased by 18% to 249,565 units, as reported in the SEC Form 4 filing. Looking at the historical insider transactions at electroCore Inc., several interesting patterns emerge when analyzing the timing, price, volume, purchaser's role, and more. On August 8, 2023, Goldstein Julie Ann and Cuneo F Peter both filed SEC Form 4 report